Category: PharmaceuticalsSyndicate content

Valeant sues Allergan for special meeting after show of shareholder support

August 25, 2014 by Arezu Sarvestani

Valeant Pharmaceuticals files a lawsuit aiming to force Allergan to hold a special shareholder meeting after hand-delivering 1,500 pages of documents showing shareholder support.

Valeant files new lawsuit in Allergan acquisition saga

Allergan can't delay shareholder vote on hostile Valeant bid

August 22, 2014 by Brad Perriello

Valeant Pharmaceuticals and Pershing Square Capital Management reportedly plan to ask Allergan for a shareholder vote on their hostile takeover attempt, after a federal judge rules that Allergan's insider trading lawsuit won't delay the meeting.

Allergan can't delay shareholder vote on hostile Valeant bid

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover

August 20, 2014 by Brad Perriello

Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.

Report: Allergan solicits Salix in bid to thwart hostile Valeant takeover

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

August 14, 2014 by Brad Perriello

The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO

Report: Valeant's hostile takeover hopes fade as Allergan war continues

August 6, 2014 by Arezu Sarvestani

Allergan uses the occasion of unrequited buyer Valeant Pharmaceuticals' latest financial report to drive home allegations that Valeant isn't being upfront about its business and accounting practices.

Allergan attacks activist investor's latest earnings report

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Cardinal Health struggles but beats The Street in Q4

August 4, 2014 by Arezu Sarvestani

Healthcare giant Cardinal Health posts declines in its major drug business during its 4th quarter, but cost-control measures and gains in its smaller medical supplies division help beat analysts' estimates.

Cardinal Health struggles but beats The Street in Q4

Ohio healthcare giant Cardinal Health (NYSE:CAH) got no Wall Street love after posting estimate-beating earnings today.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter sheds vaccines biz for $635M

July 31, 2014 by Arezu Sarvestani

Illinois healthcare giant Baxter sells its commercial vaccines division ahead of a larger transformation that will split its medical products and pharmaceuticals businesses into separate entities.

`Baxter sheds vaccines biz for $635M

Baxter (NYSE:BAX) agreed to offload its commercial vaccines business to pharmaceutical rival Pfizer (NYSE:PFE) for $635 million in cash.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp